Pulmocide

Pulmocide terminates its phase 3 trial of an inhaled antifungal after patients treated with the drug showed lower response rates and a higher mortality rate compared to the control group. The decision follows observed safety and efficacy concerns in the trial. The investigational therapy targets fungal infections but failed to demonstrate sufficient benefit over standard care.

Jan 2026Fierce BiotechNews article

Pulmocide demonstrates antifungal safety and efficacy in phase 2 OPERA-S trial data, preventing and eradicating infections without side effects linked to current treatments. The study highlights its potential as an alternative to existing antifungal therapies. Researchers emphasize its ability to address unmet needs in infection management.

Apr 2024Fierce BiotechNews article

Pulmocide Ltd. appoints **Matt Dallas** as Chief Financial Officer and **Ashish Sagrolikar** as Chief Commercial Officer to support its inhaled therapies for acute and chronic respiratory diseases. The late-stage biopharmaceutical company expands its leadership to advance novel treatments targeting serious respiratory conditions. Both executives join to strengthen financial and commercial operations.

Jun 2023SV Health InvestorsNews article

Pulmocide Ltd. secures $52 million in Series C funding to advance late-stage trials of its inhaled antifungal therapy, Opelconazole. The round includes new investors Pictet Alternative Advisors and Vivo Capital alongside existing backers like SV Health Investors and Johnson & Johnson Innovation. The company targets treatments for serious acute and chronic respiratory diseases.

Dec 2022BioSpaceNews article